ASCAT

Global Blood Therapeutics Inc (NASDAQ: GBT) shares are down 7.4 percent Wednesday on no official news from the company. However, a source familiar with the matter has told Benzinga that investors are concerned that the company’s 28-day efficacy timeline for GBT440 may need to be extended to...